12:00 AM
 | 
Jan 18, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Centanafadine SR: Phase IIb started

Neurovance began a double-blind, placebo-controlled, crossover, U.S. Phase IIb trial to evaluate oral centanafadine SR starting at 100 mg twice daily titrated up to 400 mg twice...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD